Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care.
Woodhouse B, Pattison S, Segelov E, Singh S, Parker K, Kong G, Macdonald W, Wyld D, Meyer-Rochow G, Pavlakis N, Conroy S, Gordon V, Koea J, Kramer N, Michael M, Wakelin K, Asif T, Lo D, Price T, Lawrence B; Commonwealth Neuroendocrine Tumour Collaboration (CommNETs). Woodhouse B, et al. Among authors: wyld d. J Clin Med. 2019 Sep 12;8(9):1455. doi: 10.3390/jcm8091455. J Clin Med. 2019. PMID: 31547431 Free PMC article.
Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors.
Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E; Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group. Singh S, et al. Among authors: wyld d. JAMA Oncol. 2018 Nov 1;4(11):1597-1604. doi: 10.1001/jamaoncol.2018.2428. JAMA Oncol. 2018. PMID: 30054622
Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention.
Guccione L, Gough K, Drosdowsky A, Fisher K, Price T, Pavlakis N, Khasraw M, Wyld D, Ransom D, Kong G, Rogers M, Leyden S, Leyden J, Michael M, Schofield P. Guccione L, et al. Among authors: wyld d. JMIR Res Protoc. 2019 Dec 3;8(12):e14361. doi: 10.2196/14361. JMIR Res Protoc. 2019. PMID: 31793892 Free PMC article.
The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (18 F) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumors.
Lung MS, Hicks RJ, Pavlakis N, Link E, Jefford M, Thomson B, Wyld DK, Liauw W, Akhurst T, Kuru N, Michael M. Lung MS, et al. Asia Pac J Clin Oncol. 2020 Jun;16(3):150-157. doi: 10.1111/ajco.13307. Epub 2020 Feb 7. Asia Pac J Clin Oncol. 2020. PMID: 32030887 Clinical Trial.
Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours.
Elston MS, Love A, Kevat D, Carroll R, Siow ZR, Pattison S, Boyle V, Segelov E, Strickland AH, Wyld D, Gauci R, Kennedy K, Ransom D; Commonwealth Neuroendocrine Tumour Collaboration (CommNETs). Elston MS, et al. Among authors: wyld d. Cancer Med. 2021 Dec;10(23):8405-8411. doi: 10.1002/cam4.4345. Epub 2021 Oct 26. Cancer Med. 2021. PMID: 34697905 Free PMC article.
Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide Therapy.
Li M, Chan DL, Tapia Rico G, Cehic G, Lawrence B, Wyld D, Pattison DA, Kong G, Hicks R, Michael M, Kiberu AD, Lim J, Clifton-Bligh R, Tsang V, Roach PJ, Leyden J, Diakos CI, Price TJ, Pavlakis N. Li M, et al. Among authors: wyld d. Neuroendocrinology. 2023;113(3):281-288. doi: 10.1159/000526848. Epub 2022 Sep 1. Neuroendocrinology. 2023. PMID: 36049462 Free article. Review.
136 results